Cernostics saves lives by developing and commercializing molecular diagnostic tests for cancer and cancer related disease
Cernostics develops new molecular diagnostic tests for the fight against cancer. Our first commercial test predicts risk for developing Esophageal Cancer in patients with Barrett's Esophagus. 6 million people world-wide have Barretts, and physicians have great difficulty determining which patients are at greatest risk for cancer. This leads to imprecise treatment and patient uncertainty in healthcare systems. Our test addresses these issues.